MedTrace Logo

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

NCT06092892 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-05-11

No results posted yet for this study

Summary

The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.

Conditions

  • Breast Cancer
  • Axillary Nodal Disease
  • Female Breast Cancer
  • Axilla; Breast
  • Mastectomy; Lymphedema
  • Tumor, Breast

Interventions

PROCEDURE

Breast Surgery (BCS or mastectomy) with TAD/SNB

Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy

RADIATION

Adjuvant Radiation Therapy

Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy

Sponsors & Collaborators

  • Alice Chung

    lead OTHER

Principal Investigators

  • Alice Chung, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-07
Primary Completion
2031-04-30
Completion
2031-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06092892 on ClinicalTrials.gov